Evidence map›Paper›PMID 19531496›Full record

ArticleThe Journal of biological chemistry2009

Characterization of phospholipase C gamma enzymes with gain-of-function mutations.

Katy L Everett, Tom D Bunney, Youngdae Yoon, Fernando Rodrigues-Lima, Richard Harris, Paul C Driscoll, Koichiro Abe, Helmut Fuchs, Martin Hrabé de Angelis, Philipp Yu and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 60 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Case Report:Frontiers in immunology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. NovelFrontiers in immunology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 5 countries.

Katy L EverettSection of Cell and Molecular Biology, Chester Beatty Laboratories, The Institute of Cancer Research, London SW3 6JB, United Kingdom.
Tom D Bunney
Youngdae Yoon
Fernando Rodrigues-Lima
Richard Harris
Paul C Driscoll
Koichiro Abe
Helmut Fuchs
Martin Hrabé de Angelis
Philipp Yu
Wohnwa Cho
Matilda Katan
Institute of Cancer Research · GBHelmholtz Zentrum München · DEUniversity of Illinois Chicago · USMedical Research Council · GBPhilipps University of Marburg · DETokai University · JPUniversité Paris Cité · FRUniversity College London · GB

Funding

Cancer Research UKMedical Research Council MC_U117574559
6 · The paper itself

Abstract

Phospholipase C gamma isozymes (PLC gamma 1 and PLC gamma 2) have a crucial role in the regulation of a variety of cellular functions. Both enzymes have also been implicated in signaling events underlying aberrant cellular responses. Using N-ethyl-N-nitrosourea (ENU) mutagenesis, we have recently identified single point mutations in murine PLC gamma 2 that lead to spontaneous inflammation and autoimmunity. Here we describe further, mechanistic characterization of two gain-of-function mutations, D993G and Y495C, designated as ALI5 and ALI14. The residue Asp-993, mutated in ALI5, is a conserved residue in the catalytic domain of PLC enzymes. Analysis of PLC gamma 1 and PLC gamma 2 with point mutations of this residue showed that removal of the negative charge enhanced PLC activity in response to EGF stimulation or activation by Rac. Measurements of PLC activity in vitro and analysis of membrane binding have suggested that ALI5-type mutations facilitate membrane interactions without compromising substrate binding and hydrolysis. The residue mutated in ALI14 (Tyr-495) is within the spPH domain. Replacement of this residue had no effect on folding of the domain and enhanced Rac activation of PLC gamma 2 without increasing Rac binding. Importantly, the activation of the ALI14-PLC gamma 2 and corresponding PLC gamma 1 variants was enhanced in response to EGF stimulation and bypassed the requirement for phosphorylation of critical tyrosine residues. ALI5- and ALI14-type mutations affected basal activity only slightly; however, their combination resulted in a constitutively active PLC. Based on these data, we suggest that each mutation could compromise auto-inhibition in the inactive PLC, facilitating the activation process; in addition, ALI5-type mutations could enhance membrane interaction in the activated state.

Indexed as

Alkylating AgentsAmino Acid SequenceAnimalsCalorimetryCatalytic DomainCell LineChlorocebus aethiopsCOS CellsDrosophilaEthylnitrosoureaIsoenzymesMagnetic Resonance SpectroscopyMiceMolecular Sequence DataMutationPhospholipase C gammaAlkylating AgentsEthylnitrosoureaIsoenzymesPhospholipase C gamma

Identifiers

PMID19531496
PMCPMC2755714
OpenAlexW2132419558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.